Expression of tumor-associated calcium signal transducer 2 in patients with salivary adenoid cystic carcinoma: Correlation with clinicopathological features and prognosis

Oncology Letters

Volumn 8, Issue 4, 2014, Pages 1670-1674

  Xia, Yichao ^a   Li, Bo ^a   Gao, Ning ^a   Xia, Hui ^a   Men, Yi ^a   Liu, Ying ^a   Liu, Zhe ^a   Chen, Qianming ^a   Li, Longjiang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Clinicopathological feature; Prognosis; Salivary adenoid cystic carcinoma; TACSTD2

Indexed keywords

CELL SURFACE MARKER; TUMOR ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADENOID CYSTIC CARCINOMA; ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; FEMALE; GENDER; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SALIVARY GLAND TUMOR; SCORING SYSTEM;

EID: 84919430458     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2400     Document Type: Article

References (32)

1. Li LJ, Li Y, Wen YM, et al: Clinical analysis of salivary gland tumor cases in West China in past 50 years. Oral Oncol 44: 187-192, 2008.
2. Spiro RH: Salivary neoplasms: overview of a 35-year experience with 2,807 patients. Head Neck Surg 8: 177-184, 1986.
3. Gao M, Hao Y, Huang MX, et al: Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma. Int J Oral Maxillofac Surg 42: 923-928, 2013.
4. Trzpis M, McLaughlin PM, de Leij LM and Harmsen MC: Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 171: 386-395, 2007.
5. Ripani E, Sacchetti A, Corda D and Alberti S: Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer 76: 671-676, 1998.
6. Lipinski M, Parks DR, Rouse RV and Herzenberg LA: Human trophoblast cell-surface antigens defined by monoclonal antibodies. Proc Natl Acad Sci USA 78: 5147-5150, 1981.
7. Linnenbach AJ, Wojcierowski J, Wu SA, et al: Sequence investigation of the major gastrointestinal tumor-associated antigen gene family, GA733. Proc Natl Acad Sci USA 86: 27-31, 1989.
8. Guerra E, Trerotola M, Aloisi AL, et al: The Trop-2 signalling network in cancer growth. Oncogene 32: 1594-1600, 2013.
9. El Sewedy T, Fornaro M and Alberti S: Cloning of the murine TROP2 gene: conservation of a PIP2-binding sequence in the cytoplasmic domain of TROP-2. Int J Cancer 75: 324-330, 1998.
10. Wang J, Day R, Dong Y, et al: Identification of Trop-2 as an oncogene and an attractive therapeutic target in colon cancers. Mol Cancer Ther 7: 280-285, 2008.
11. Fong D, Spizzo G, Gostner JM, et al: TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol 21: 186-191, 2008.
12. Fong D, Moser P, Krammel C, et al: High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 99: 1290-1295, 2008.
13. Liu T, Liu Y, Bao X, et al: Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PloS One 8: e75864, 2013.
14. Ning S, Guo S, Xie J, Xu Y, Lu X and Chen Y: TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma. J Gastrointest Surg 17: 360-368, 2013.
15. Mühlmann G, Spizzo G, Gostner J, et al: TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol 62: 152-158, 2009.
16. Bignotti E, Todeschini P, Calza S, et al: Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer 46: 944-953, 2010.
17. da Cruz Perez DE, de Abreu Alves F, Nobuko Nishimoto I, et al: Prognostic factors in head and neck adenoid cystic carcinoma. Oral Oncol 42: 139-146, 2006.
18. Seifert G and Sobin LH: The World Health Organization's Histological Classification of Salivary Gland Tumors. A commentary on the second edition. Cancer 70: 379-385, 1992.
19. Linnenbach AJ, Seng BA, Wu S, et al: Retroposition in a family of carcinoma-associated antigen genes. Mol Cell Biol 13: 1507-1515, 1993.
20. Nakashima K, Shimada H, Ochiai T, et al: Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer 112: 1029-1035, 2004.
21. Guerra E, Trerotola M, Dell'Arciprete R, et al: A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res 68: 8113-8121, 2008.
22. Cubas R, Zhang S, Li M, Chen C and Yao Q: Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer 9: 253, 2010.
23. Biliran H Jr, Wang Y, Banerjee S, et al: Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Clin Cancer Res 11: 6075-6086, 2005.
24. Trerotola M, Li J, Alberti S and Languino LR: Trop-2 inhibits prostate cancer cell adhesion to fibronectin through the β1 integrin-RACK1 axis. J Cell Physiol 227: 3670-3677, 2012.
25. Trerotola M, Jernigan DL, Liu Q, et al: Trop-2 promotes prostate cancer metastasis by modulating β(1) integrin functions. Cancer Res 73: 3155-3167, 2013.
26. de Bono JS, Tolcher AW, Forero A, et al: ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res 10: 7555-7565, 2004.
27. Mosolits S, Markovic K, Frodin JE, et al: Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I-and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin Cancer Res 10: 5391-5402, 2004.
28. Bignotti E, Ravaggi A, Romani C, et al: Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-trop-2 monoclonal antibody. Int J Gynecol Cancer 21: 1613-1621, 2011.
29. Raji R, Guzzo F, Carrara L, et al: Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. J Exp Clin Cancer Res 30: 106, 2011.
30. Varughese J, Cocco E, Bellone S, et al: Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody. Cancer 117: 3163-3172, 2011.
31. Govindan SV, Stein R, Qu Z, et al: Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res Treat 84: 173-182, 2004.
32. Lin H, Zhang H, Wang J, et al: A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo. Int J Cancer 34: 1239-1249, 2014.